Patents by Inventor P ANANTHA

P ANANTHA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230365631
    Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Application
    Filed: May 12, 2023
    Publication date: November 16, 2023
    Inventors: Ravi P. Anantha, Thomas G. Evans, Aurelio M. Bonavia
  • Patent number: 11692014
    Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: July 4, 2023
    Assignee: International AIDS Vaccine Initiative, Inc.
    Inventors: Ravi P. Anantha, Thomas G. Evans, Aurelio M. Bonavia
  • Patent number: 11091775
    Abstract: The present disclosure provides cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: August 17, 2021
    Assignees: Oregon Health and Science University, International AIDS Vaccine Initative, Inc.
    Inventors: Thomas G. Evans, Ravi P. Anantha, Aurelio M. Bonavia, Dominick J. Laddy, Louis Picker, Scott Hansen, Guangwu Xu
  • Publication number: 20200181209
    Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Application
    Filed: August 15, 2019
    Publication date: June 11, 2020
    Inventors: Ravi P. Anantha, Thomas G. Evans, Aurelio M. Bonavia
  • Patent number: 10598853
    Abstract: Various embodiments may provide an optical structure. The optical structure may include a substrate. The optical structure may also include a core layer configured to carry optical light. The core layer may include germanium. The optical structure may further include an intermediate layer separating the substrate and the core layer so that the substrate is isolated from the core layer. The intermediate layer may include one or more materials selected from a group consisting of III-V materials, dielectric materials, and chalcogenide materials. A width of the core layer may be smaller than a width of the intermediate layer. A refractive index of the core layer may be more than 4. A refractive index of the intermediate layer may be smaller than 3.6.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: March 24, 2020
    Assignees: NANYANG TECHNOLOGICAL UNIVERSITY, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Chuan Seng Tan, Wei Li, P Anantha, Kwang Hong Lee, Shuyu Bao, Lin Zhang
  • Patent number: 10428122
    Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: October 1, 2019
    Assignee: International AIDS Vaccine Initiative, Inc.
    Inventors: Ravi P. Anantha, Thomas G. Evans, Aurelio M. Bonavia
  • Publication number: 20190033523
    Abstract: Various embodiments may provide an optical structure. The optical structure may include a substrate. The optical structure may also include a core layer configured to carry optical light. The core layer may include germanium. The optical structure may further include an intermediate layer separating the substrate and the core layer so that the substrate is isolated from the core layer. The intermediate layer may include one or more materials selected from a group consisting of III-V materials, dielectric materials, and chalcogenide materials. A width of the core layer may be smaller than a width of the intermediate layer. A refractive index of the core layer may be more than 4. A refractive index of the intermediate layer may be smaller than 3.6.
    Type: Application
    Filed: February 10, 2017
    Publication date: January 31, 2019
    Applicants: NANYANG TECHNOLOGICAL UNIVERSITY, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Chuan Seng TAN, Wei LI, P ANANTHA, Kwang Hong LEE, Shuyu BAO, Lin ZHANG
  • Publication number: 20180016599
    Abstract: The present disclosure provides cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Application
    Filed: June 21, 2017
    Publication date: January 18, 2018
    Inventors: Thomas G. Evans, Ravi P. Anantha, Aurelio M. Bonavia, Dominick J. Laddy, Louis Picker, Scott Hansen, Guangwu Xu
  • Publication number: 20170362284
    Abstract: The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Application
    Filed: June 16, 2017
    Publication date: December 21, 2017
    Inventors: Ravi P. Anantha, Thomas G. Evans, Aurelio M. Bonavia
  • Publication number: 20150006665
    Abstract: In at least some examples, a computer system includes a processor and a storage device coupled to the processor. The storage device stores a storage provisioning negotiation module that, when executed, causes the processor to determine whether a received storage provisioning request is approved. If the received storage provisioning request is not approved, the storage provisioning negotiation module causes the processor to determine a set of alternative storage provisioning options based on predetermined negotiation rules.
    Type: Application
    Filed: January 20, 2012
    Publication date: January 1, 2015
    Inventors: Vikram Krishnamurthy, Anuradha P. Anantha, Vasavi Sagi, Surendra Sapra
  • Patent number: 8658136
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: February 25, 2014
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, Jr.
  • Publication number: 20130224242
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Application
    Filed: April 8, 2013
    Publication date: August 29, 2013
    Applicant: Aeras Global TB Vaccine Foundation
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, JR.
  • Patent number: 8414884
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: April 9, 2013
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, Jr.
  • Publication number: 20110086066
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Application
    Filed: December 10, 2010
    Publication date: April 14, 2011
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, JR.
  • Patent number: 7883696
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: February 8, 2011
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, Jr.
  • Publication number: 20100003219
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Application
    Filed: September 11, 2009
    Publication date: January 7, 2010
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, JR.
  • Patent number: 7608256
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: October 27, 2009
    Assignee: Aeras Global TB Vaccine Foundation
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, Jr.
  • Publication number: 20090068222
    Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.
    Type: Application
    Filed: September 12, 2007
    Publication date: March 12, 2009
    Inventors: Jerald C. Sadoff, Mohamad F. Jamiluddin, Ravi P. Anantha, John F. Fulkerson, JR.